Myosin phosphatase is inactivated by caspase-3 cleavage and phosphorylation of myosin phosphatase targeting subunit 1 during apoptosis. 2013

Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
Cell-Free Science and Technology Research Center and Venture Business Laboratory, Ehime University, Matsuyama, Ehime 790-8577, Japan.

In nonapoptotic cells, the phosphorylation level of myosin II is constantly maintained by myosin kinases and myosin phosphatase. During apoptosis, caspase-3-activated Rho-associated protein kinase I triggers hyperphosphorylation of myosin II, leading to membrane blebbing. Although inhibition of myosin phosphatase could also contribute to myosin II phosphorylation, little is known about the regulation of myosin phosphatase in apoptosis. In this study, we have demonstrated that, in apoptotic cells, the myosin-binding domain of myosin phosphatase targeting subunit 1 (MYPT1) is cleaved by caspase-3 at Asp-884, and the cleaved MYPT1 is strongly phosphorylated at Thr-696 and Thr-853, phosphorylation of which is known to inhibit myosin II binding. Expression of the caspase-3 cleaved form of MYPT1 that lacked the C-terminal end in HeLa cells caused the dissociation of MYPT1 from actin stress fibers. The dephosphorylation activity of myosin phosphatase immunoprecipitated from the apoptotic cells was lower than that from the nonapoptotic control cells. These results suggest that down-regulation of MYPT1 may play a role in promoting hyperphosphorylation of myosin II by inhibiting the dephosphorylation of myosin II during apoptosis.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D043263 Myosin-Light-Chain Phosphatase A phosphoprotein phosphatase that is specific for MYOSIN LIGHT CHAINS. It is composed of three subunits, which include a catalytic subunit, a myosin binding subunit, and a third subunit of unknown function. Calponin Phosphatase,Myosin Light Chain Phosphatase,Myosin Phosphatase,Smooth Muscle MBP,Smooth Muscle Myosin-bound Phosphatase,Smooth Muscle Phosphatase-I,Smooth Muscle Phosphatase-II,Muscle Phosphatase-II, Smooth,Phosphatase, Calponin,Phosphatase, Myosin,Phosphatase, Myosin-Light-Chain,Phosphatase-II, Smooth Muscle,Smooth Muscle Myosin bound Phosphatase,Smooth Muscle Phosphatase I,Smooth Muscle Phosphatase II
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
October 2006, The Journal of biological chemistry,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
April 2005, Experimental cell research,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
July 2014, The Journal of physiology,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
February 1999, The Journal of cell biology,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
June 2005, Oncogene,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
November 2009, Proteins,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
October 2019, Cell cycle (Georgetown, Tex.),
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
January 2002, The Journal of biological chemistry,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
June 2016, The Journal of physiology,
Takahiro Iwasaki, and Takeshi Katayama, and Kazuhiro Kohama, and Yaeta Endo, and Tatsuya Sawasaki
August 2013, Oncology reports,
Copied contents to your clipboard!